This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. ALLO, ATYR, AURA, SLDB, GLUE, DBVT, ITOS, CDTX, CMPX, and CADLShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Allogene Therapeutics (ALLO), Atyr PHARMA (ATYR), Aura Biosciences (AURA), Solid Biosciences (SLDB), Monte Rosa Therapeutics (GLUE), DBV Technologies (DBVT), iTeos Therapeutics (ITOS), Cidara Therapeutics (CDTX), Compass Therapeutics (CMPX), and Candel Therapeutics (CADL). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Allogene Therapeutics Atyr PHARMA Aura Biosciences Solid Biosciences Monte Rosa Therapeutics DBV Technologies iTeos Therapeutics Cidara Therapeutics Compass Therapeutics Candel Therapeutics Allogene Therapeutics (NASDAQ:ALLO) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Does the MarketBeat Community prefer ALLO or PRTO? Allogene Therapeutics received 18 more outperform votes than Proteon Therapeutics when rated by MarketBeat users. However, 69.21% of users gave Proteon Therapeutics an outperform vote while only 66.21% of users gave Allogene Therapeutics an outperform vote. CompanyUnderperformOutperformAllogene TherapeuticsOutperform Votes29066.21% Underperform Votes14833.79% Proteon TherapeuticsOutperform Votes27269.21% Underperform Votes12130.79% Does the media favor ALLO or PRTO? In the previous week, Allogene Therapeutics had 18 more articles in the media than Proteon Therapeutics. MarketBeat recorded 18 mentions for Allogene Therapeutics and 0 mentions for Proteon Therapeutics. Allogene Therapeutics' average media sentiment score of 0.06 beat Proteon Therapeutics' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Allogene Therapeutics Neutral Proteon Therapeutics Neutral Do institutionals & insiders hold more shares of ALLO or PRTO? 83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, ALLO or PRTO? Proteon Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$22K9,990.84-$327.27M-$1.33-0.76Proteon TherapeuticsN/AN/A-$20.73M-$1.15-2.72 Which has more risk and volatility, ALLO or PRTO? Allogene Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Do analysts prefer ALLO or PRTO? Allogene Therapeutics currently has a consensus target price of $8.44, indicating a potential upside of 740.24%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ALLO or PRTO more profitable? Proteon Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -52.13% -41.29% Proteon Therapeutics N/A N/A -118.68% SummaryAllogene Therapeutics beats Proteon Therapeutics on 10 of the 15 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.42M$2.81B$5.23B$8.47BDividend YieldN/A1.92%4.99%4.16%P/E Ratio-2.7229.5526.4519.69Price / SalesN/A389.20397.54122.37Price / CashN/A168.6838.3134.62Price / Book-52.172.966.654.50Net Income-$20.73M-$72.17M$3.22B$248.02M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$3.13-2.8%N/A-3.6%$69.42MN/A-2.7217ALLOAllogene Therapeutics3.6719 of 5 stars$1.35-17.0%$9.29+590.6%-67.8%$294.60M$22,000.00-0.86310Earnings ReportAnalyst ForecastNews CoverageATYRAtyr PHARMA2.7466 of 5 stars$3.28-8.5%$18.60+467.9%N/A$291.01M$235,000.00-3.4853Analyst RevisionNews CoverageAURAAura Biosciences2.4926 of 5 stars$5.51-6.9%$22.75+312.7%-34.9%$277.24MN/A-3.1950Earnings ReportNews CoverageGap DownSLDBSolid Biosciences3.8351 of 5 stars$3.40-19.7%$15.67+361.5%-74.4%$263.89M$8.09M-1.12100Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageHigh Trading VolumeGLUEMonte Rosa Therapeutics2.1873 of 5 stars$4.22-9.0%$15.50+267.7%-26.0%$259.27M$75.62M-2.3090Earnings ReportAnalyst RevisionNews CoverageDBVTDBV Technologies3.0799 of 5 stars$9.46+2.3%$15.50+63.8%+95.6%$259.11M$15.73M-2.1080Positive NewsGap DownITOSiTeos Therapeutics2.8287 of 5 stars$6.65-7.5%$25.50+283.5%-54.5%$253.76M$35M-2.1090Analyst DowngradeNews CoverageCDTXCidara Therapeutics4.4389 of 5 stars$19.88-7.5%$39.14+96.9%+47.5%$249.43M$1.28M-0.7890Earnings ReportCMPXCompass Therapeutics3.7967 of 5 stars$1.69-9.4%$13.38+693.8%+23.8%$233.01M$850,000.00-4.5520Earnings ReportAnalyst RevisionCADLCandel Therapeutics2.2665 of 5 stars$4.60-7.6%$21.00+356.5%-50.1%$227.14M$120,000.00-2.6660Earnings Report Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Atyr PHARMA Alternatives Aura Biosciences Alternatives Solid Biosciences Alternatives Monte Rosa Therapeutics Alternatives DBV Technologies Alternatives iTeos Therapeutics Alternatives Cidara Therapeutics Alternatives Compass Therapeutics Alternatives Candel Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRTO Stock Free PRTO Stock Alerts